The White House is “hopeful” of some “good news” in relation to a coronavirus vaccination and other treatments in the coming days, according to one senior official.
More than 1,000 Americans died for five days straight last week for the first time since May, with increasing caseloads coinciding with falling support for Donald Trump in the polls.
Chief of Staff Mark Meadows said the government has been “working around the clock” as it continues its battle against coronavirus.
Speaking to ABC News, he said: “I’m hopeful that, in the next couple of days, that we will have some very good news on the therapeutic and vaccine fronts, as we try to address this China virus.”
For updates on coronavirus, follow our live blog HERE
Having been asked how President Trump intends to claw back voters’ support in light of rival Joe Biden’s surge up the polls, Mr Meadows said his administration has to “focus” on helping those suffering with the disease.
“I think we have to focus, obviously, on trying to make sure that there’s therapeutics, vaccines and a number of mitigation therapies, hopefully, for those that are suffering from the coronavirus,” he said.
“I can tell you that we have been working around the clock. The president has been very clear.
“Whatever amount of money, whatever amount of time needs to be invested, we’re doing that.
“We’re hopeful that, with some of the breakthrough technology on therapeutics, that we will be able to announce some new therapies in the coming days.”
He went on to say, the political world throws up many obstacles which can’t be controlled, describing the pandemic as something “unexpected”.
“And, as we look at this, it’s trying to make sure that we have got our entire team there to provide the relief that so many Americans are looking for and the hope that so many Americans are looking for,” he added.
Moderna Inc said on Sunday it has received an additional $472 million from the US government’s Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.
The US-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna’s vaccine candidate.
In April, Moderna had received $483 million from the US federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the US National Institutes of Health.